In a cancer once called a “death sentence” for children, a tiny experimental trial has left four kids alive years longer than anyone expected — and one child’s brain tumor has vanished from scans for more than four years.

Story Snapshot

• New cell therapy helped four children with deadly brain cancers survive far beyond normal expectations, including one complete disappearance of a tumor.
• The treatment, a customized immune cell therapy called CAR T, shrank tumors and restored lost abilities like walking, hearing, and taste in most patients.
• Doctors call the results “remarkable” and “without precedent,” but they stress the trials are small and meant to test safety, not prove a cure.
• The therapy is complex, extremely expensive, and still experimental, raising hard questions about who will benefit if it works.

Deadly Childhood Brain Cancer Meets a New Kind of Treatment

Diffuse intrinsic pontine glioma, often grouped with diffuse midline gliomas, is one of the most feared childhood brain cancers. These tumors grow in the brainstem, a critical area that controls breathing, movement, and basic body functions. Surgery is nearly impossible, and radiation only slows the disease for a short time. For decades, doctors have told families that almost every child with this diagnosis will die within about a year, and “nothing has ever worked” to change that.

In two early clinical trials, researchers tried a new approach using chimeric antigen receptor T cells, known as CAR T cells. Doctors took each child’s own immune cells, reprogrammed them in a lab to recognize a protein on the tumor, and then put the cells back into the child’s body. In one study from Stanford University, the CAR T cells were designed to target a molecule called GD2, which sits on the surface of many diffuse midline glioma cells. Some children received the cells by vein first, then through a small port directly into the fluid spaces of the brain.

Four Children Beat the Odds, One Tumor Disappears

Across the small trials, doctors tracked 11 children and young adults treated with the GD2-targeting CAR T cell therapy. Nine of the 11 showed clear neurological improvement, meaning their day-to-day brain and body functions became better. As the tumors shrank, some kids regained lost abilities, like walking again, hearing better, and even tasting food after those senses had faded. One girl went from using a wheelchair to walking within weeks of starting treatment, according to lead researcher Dr. Michelle Monje at Stanford.

For three of the treated patients, survival time broke all previous patterns for this cancer. These children lived roughly 3.5 to 4.5 years after starting CAR T therapy, far beyond the typical survival of about 11 months from diagnosis. In the most dramatic case, one child’s tumor shrank away completely and has not come back. Brain scans show no sign of cancer, and this complete response has lasted more than four years since diagnosis, the first such result ever reported for this type of tumor.

Why Doctors Say “Promising” Instead of “Cure”

Researchers and cancer centers describe these outcomes as “remarkable,” “without precedent,” and a major break from the grim history of diffuse intrinsic pontine glioma. Yet they also stress that these were phase 1 trials, which are mainly designed to test safety and dosing instead of proving cures. Only one of the 11 patients had a complete disappearance of the tumor. Most others saw tumors shrink by different amounts or stabilize, and some later had their cancers grow again.

Median survival in one trial reached about 19.8 months after diagnosis, nearly double the historic median of around 11 months for this disease. That is a big step forward but still means half the patients died within roughly two years. Doctors caution that longer-term follow-up, more patients, and randomized trials comparing CAR T therapy to standard care are needed to know how often such dramatic responses will happen. They openly say “much work remains” to refine the approach and to understand which children benefit the most.

Risks, Side Effects, and the Challenge of Access

CAR T therapy is powerful, but it is not easy or risk-free. In the GD2 trial, several patients developed inflammation in the brain and spinal cord after treatment. Doctors managed these side effects with steroids and careful monitoring, but they can be serious. Experience with CAR T in leukemia and other cancers has helped teams recognize and treat complications like cytokine release syndrome, a strong immune reaction, and neurologic symptoms. Still, these risks add to the stress families already face in deciding on experimental care.

Everyone's racing to engineer T cells for solid tumors. One of the most striking pediatric brain-cancer results this year came from T cells that weren't engineered at all.

Children's National just published a Phase 1 in Nature Medicine: multi-antigen T cells targeting WT1, PRAME…

— BioSignal (@BioSignal) July 7, 2026

The treatment also raises hard questions about cost and fairness. CAR T therapies already used for blood cancers often cost around hundreds of thousands of dollars per patient, and they require specialized labs and hospital teams. Diffuse intrinsic pontine glioma affects only a few hundred children a year in the United States, which makes large trials harder to run and slows progress. The United States Food and Drug Administration granted the GD2 therapy a special “Regenerative Medicine Advanced Therapy” status that recognizes its promise but does not yet approve it as standard care. Families who want access may depend on clinical trials or charity support rather than insurance coverage.

Hope, Caution, and a System That Struggles to Keep Up

For parents on both the right and the left who feel the system is broken, this story hits a nerve. On one hand, it shows that determined scientists in universities and children’s hospitals can push past decades of failure and give dying kids real hope. On the other hand, it shows how slowly that hope moves through the larger health system, weighed down by cost, red tape, and risk concerns that often seem more focused on institutions than on families.

Experts point out that almost all progress against rare childhood cancers has come through clinical trials, not routine care. That means brave families must agree to experimental treatments while knowing the odds are unknown. The early CAR T results for diffuse intrinsic pontine glioma suggest the old belief that “nothing works” may finally be cracking. Whether this becomes a true path to cure for many children will depend on long-term data, broader trials, and a health system that chooses to back breakthrough care instead of letting it stay out of reach.

Sources:

newscientist.com, pcrf-kids.org, ludwigcancerresearch.org, cancertodaymag.org, med.stanford.edu, cancer.gov, abbiesarmy.co.uk, facebook.com, chop.edu